We also reported novel FGFR fusion events in NSCLC patients, including SLC20A2-FGFR1, FGFR2-INA, and FGFR4-GAPGEFL1; thus, highlighting potential therapeutic targets for the management of such patients. This evidence concerns the gene INA and non-small cell lung carcinoma.